Sangamo Therapeutics (SGMOQ) Net Margin (2010 - 2025)

Sangamo Therapeutics' Net Margin history runs 16 years deep, the most recent figure standing at 263.0% for Q4 2025.

• On a quarterly basis, Net Margin rose 9694.0% year-over-year to 263.0% in Q4 2025; TTM through Dec 2025 was 310.81%, a 13596.0% decrease from a year earlier, with the FY2025 full-year figure at 310.81%, down 14136.0% from the prior year.
• Net Margin grew to 263.0% in Q4 2025 per SGMOQ's latest filing, from 6012.05% in the prior quarter.
• Across five years, Net Margin topped out at 18.99% in Q3 2024 and bottomed at 10205.61% in Q1 2024.
• The 5-year median for Net Margin is 195.82% (2022), against an average of 1730.84%.
• Across the five-year window, Net Margin plunged 1021899 bps in 2024 and soared 1003914 bps in 2025, its largest moves.
• Year by year, Net Margin stood at 133.98% in 2021, then slumped by 42 bps to 190.76% in 2022, then slumped by 1448 bps to 2952.74% in 2023, then jumped by 88 bps to 359.94% in 2024, then gained by 27 bps to 263.0% in 2025.
• Per Business Quant, the three latest SGMOQ Net Margin figures stand at 263.0% (Q4 2025), 6012.05% (Q3 2025), and 109.18% (Q2 2025).